Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
about
An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machineDiverse mechanisms of AKT pathway activation in human malignancyFeatures of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinityHSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivoSynthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90Synthesis of macrolactam analogues of radicicol and their binding to heat shock protein Hsp90Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug designMolecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesGambogic acid, a natural product inhibitor of Hsp90Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.A screening assay to identify agents that enhance T-cell recognition of human melanomasHsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.Use of kinase inhibitors to correct ΔF508-CFTR function.Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.Targeting protein-protein interactions as an anticancer strategyComparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.Hsp90 interacts with inducible NO synthase client protein in its heme-free state and then drives heme insertion by an ATP-dependent process.Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cellsHeat shock protein 90 inhibition by 17-DMAG attenuates abdominal aortic aneurysm formation in miceHeat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cellsBCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability.Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.The rapid and direct determination of ATPase activity by ion exchange chromatography and the application to the activity of heat shock protein-90Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitorHeat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells.Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response gene expression in metastatic melanoma cellsInhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.Antileukemic Scalarane Sesterterpenoids and Meroditerpenoid from Carteriospongia (Phyllospongia) sp., Induce Apoptosis via Dual Inhibitory Effects on Topoisomerase II and Hsp90.In vitro and in vivo anti-malarial activity of novel harmine-analog heat shock protein 90 inhibitors: a possible partner for artemisinin.Chronic myeloid leukemia stem cells and developing therapies.The biological and therapeutic relevance of mRNA translation in cancer.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.Hsp90, the concertmaster: tuning transcription.
P2860
Q21134999-01DA180B-44F9-448B-8AB9-F547C31F65BFQ26851604-6EC3D6CC-CF0D-4F5E-BDA2-DD1BCAC23B59Q26996645-1261BB76-69D2-40AE-BEE7-C18D0B54FF03Q27320833-46AA2DE3-8530-40E8-9BA1-3FB7AEE99BEBQ27676888-33B931EF-D783-4F01-BE31-AF23AA48393CQ27688922-E1C4863E-6418-4681-8DCA-3275199E0019Q28534499-A08C4756-9D4D-42BC-8821-144E5D816CE7Q33715640-C1652E0F-9D07-47F7-A213-4BD275690A06Q33870322-189493B2-492D-4017-B429-D8947A6A5C94Q34022729-7D19C7CC-2103-4767-8F4A-71A7C4A397ADQ34074758-988C297D-C3BF-4BC2-9F01-FDEE3AB7C7FDQ34140962-090423D9-E525-4464-BACC-14612AD60417Q34262700-F2F41516-4831-4E7A-B998-63592EE30622Q34304720-31690E17-9242-407F-A905-D268CF9290BBQ34335802-7FB5425F-BD41-4693-9E35-2CFB07CF3BFEQ34347892-FA716117-37C4-4E70-9D0E-7D8D1AA80669Q34478388-BC318F41-449F-4684-A46C-8759B9F7FB25Q34852929-C37A2F83-D8D1-4481-B95A-CC483831E793Q35003199-41CAC4BB-5B6F-40EC-B50D-31D14A43555AQ35096555-6423FCF9-5D0A-4265-8354-0F041FAC07C7Q35437393-654F7CAF-E967-4671-A201-B643DC90ABA7Q35517613-787F5CD6-2540-44C3-8181-F8828EEE8E07Q35677312-56929A35-6497-4B29-B4FF-83A5016FEA07Q35800838-808D2C54-42EC-417F-B801-F1E7847880FDQ35849973-E4648EFD-2833-48F1-9632-58DADF0B4877Q36098943-1EC643F4-157A-415E-9B01-16ED93FB8C34Q36300140-0B0E4B70-C6C6-496F-AE76-7EFA63EE7BC3Q36588726-F61186D8-2B41-41E8-BF0C-DFFD4C4F25CFQ36656212-EC644E10-D58F-4C58-99CB-6825B6559405Q37068669-F2C90ABE-DE79-4D53-8D4D-8115EE8BCDB3Q37148194-D173E841-6E0C-4183-9D7D-202F5BA44FDCQ37296982-893A1F41-A010-4DF6-A503-450BD06D3B37Q37379572-847B929C-EA56-4CD5-9AE3-FDDDC7E7CFC0Q37460707-1C32C161-9015-40C3-8395-72392342F8BDQ37836936-A03FA3E7-0FDF-47D3-8633-2056CC9A65C6Q37848652-1E718FE2-087A-4D7D-A1B3-8D96DD967EA4Q37919976-D9BA8078-347A-425E-B3D1-5159466E9E62Q37975959-5C6CE5E7-8E11-41B6-B17E-522AD05F45A7Q38469746-662E16D7-F17A-4630-8CAF-B334FDCE514BQ38479151-B269DE8C-39CC-4E39-8990-28BA98CEF463
P2860
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@ast
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@en
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@nl
type
label
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@ast
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@en
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@nl
prefLabel
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@ast
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@en
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@nl
P2093
P1476
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
@en
P2093
Christian C Fritz
James R Porter
Kristopher M Depew
P304
P356
10.1016/J.CBPA.2010.03.019
P577
2010-04-19T00:00:00Z